BioCentury
ARTICLE | Company News

Rib-X, Sanofi deal

July 11, 2011 7:00 AM UTC

Rib-X partnered with Sanofi to discover and develop antibiotic candidates against a 20 angstrom unit of the ribosomal 50S subunit to treat drug-resistant Gram-positive and Gram-negative pathogens. The partners will jointly participate in discovery and lead selection using Rib-X's RX-04 discovery program, after which Sanofi will be responsible for clinical development of any selected compounds. Sanofi has identified four product profiles of interest, but there is no limit on the number of products the pharma can select.

Rib-X will receive $10 million up front and is eligible for an additional $9 million in near-term research payments. The company could also receive up to $186 million in milestones per product, plus up to low double-digit royalties. Rib-X will have an option to co-promote one candidate of its choice in the U.S. ...